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Background: The relationship between plaque burden and endothelial function in humans is poorly understood. IVUS was used to validate 
intracoronary (IC) salbutamol as a novel endothelium-dependent vasodilator, quantify plaque burden and assess determinants of coronary 
endothelial function.
Methods: In 25 patients with near-normal coronary angiograms, IC salbutamol was infused during IVUS-upon-Doppler Flowire imaging. Study 1: 
incremental IC salbutamol (0.15, 0.3, 0.6 μg/min) infusion (15 patients, 103 segments) and Study 2: salbutamol (0.3 μg/min) infusion pre and 
post IC administration of NG-monomethyl-L-arginine (L-NMMA) (10 patients, 82 segments). Vasomotor response [% change in segmental lumen 
volume (ΔSLV)] and plaque burden [percent atheroma volume (PAV)] was studied in 5-mm segments. Coronary blood flow (CBF) was calculated after 
each infusion.
Results: Significant salbutamol dose-response ΔSLV and ΔCBF was seen (Fig1A,B); ΔSLV was magnified in low vs high plaque burden groups. 
L-NMMA significantly abolished the salbutamol vasomotor responses supporting a nitric oxide dependent mechanism (Fig 1C,D). After multivariate 
analysis including cardiovascular risk factors, PAV, remodeling and eccentricity indices, PAV remained the only significant predictor of ΔSLV to IC 
salbutamol (coefficient -0.18, p=0.015).
Conclusions: IC salbutamol is a novel endothelium-dependent coronary vasodilator. PAV is a significant determinant of focal coronary endothelial 
function. 
